Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.
Identifieur interne : 002871 ( Ncbi/Merge ); précédent : 002870; suivant : 002872Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.
Auteurs : Michael B A. Oldstone [États-Unis] ; Hugh RosenSource :
- Current topics in microbiology and immunology [ 0070-217X ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Cytokines (immunologie), Grippe humaine (immunologie), Grippe humaine (mortalité), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Lysophospholipides (agonistes), Lysophospholipides (usage thérapeutique), Orthomyxoviridae (), Orthomyxoviridae (immunologie), Sphingosine (agonistes), Sphingosine (analogues et dérivés), Sphingosine (usage thérapeutique).
- MESH :
- agonistes : Lysophospholipides, Sphingosine.
- analogues et dérivés : Sphingosine.
- immunologie : Cytokines, Grippe humaine, Orthomyxoviridae.
- mortalité : Grippe humaine.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Lysophospholipides, Sphingosine.
- virologie : Grippe humaine.
- Animaux, Humains, Orthomyxoviridae.
English descriptors
- KwdEn :
- Animals, Cytokines (immunology), Humans, Influenza, Human (drug therapy), Influenza, Human (immunology), Influenza, Human (mortality), Influenza, Human (virology), Lysophospholipids (agonists), Lysophospholipids (therapeutic use), Orthomyxoviridae (drug effects), Orthomyxoviridae (immunology), Sphingosine (agonists), Sphingosine (analogs & derivatives), Sphingosine (therapeutic use).
- MESH :
- chemical , agonists : Lysophospholipids, Sphingosine.
- chemical , analogs & derivatives : Sphingosine.
- chemical , immunology : Cytokines.
- drug effects : Orthomyxoviridae.
- drug therapy : Influenza, Human.
- immunology : Influenza, Human, Orthomyxoviridae.
- mortality : Influenza, Human.
- chemical , therapeutic use : Lysophospholipids, Sphingosine.
- virology : Influenza, Human.
- Animals, Humans.
Abstract
Cytokine storm defines a dysregulation of and an excessively exaggerated immune response most often accompanying selected viral infections and several autoimmune diseases. Newly emerging and re-emerging infections of the respiratory tract, especially influenza, SARS, and hantavirus post considerable medical problems. Their morbidities and mortalities are often a direct result of cytokine storm. This chapter visits primarily influenza virus infection and resultant cytokine storm. It provides the compelling evidence that illuminates cytokine storm in influenza pathogenesis and the clear findings that cytokine storm is chemically tractable by therapy directed toward sphingosine-1-phosphate receptor (S1PR) modulation, specifically S1P1R agonist therapy. The mechanism(s) of how S1P1R signaling works and the pathways involved are subjects of this review.
DOI: 10.1007/978-3-319-05879-5_6
PubMed: 24728596
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001010
- to stream PubMed, to step Curation: 001010
- to stream PubMed, to step Checkpoint: 001019
Links to Exploration step
pubmed:24728596Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.</title><author><name sortKey="Oldstone, Michael B A" sort="Oldstone, Michael B A" uniqKey="Oldstone M" first="Michael B A" last="Oldstone">Michael B A. Oldstone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA, mbaobo@scripps.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA</wicri:regionArea><wicri:noRegion>USA</wicri:noRegion></affiliation></author><author><name sortKey="Rosen, Hugh" sort="Rosen, Hugh" uniqKey="Rosen H" first="Hugh" last="Rosen">Hugh Rosen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24728596</idno><idno type="pmid">24728596</idno><idno type="doi">10.1007/978-3-319-05879-5_6</idno><idno type="wicri:Area/PubMed/Corpus">001010</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001010</idno><idno type="wicri:Area/PubMed/Curation">001010</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001010</idno><idno type="wicri:Area/PubMed/Checkpoint">001019</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001019</idno><idno type="wicri:Area/Ncbi/Merge">002871</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.</title><author><name sortKey="Oldstone, Michael B A" sort="Oldstone, Michael B A" uniqKey="Oldstone M" first="Michael B A" last="Oldstone">Michael B A. Oldstone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA, mbaobo@scripps.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA</wicri:regionArea><wicri:noRegion>USA</wicri:noRegion></affiliation></author><author><name sortKey="Rosen, Hugh" sort="Rosen, Hugh" uniqKey="Rosen H" first="Hugh" last="Rosen">Hugh Rosen</name></author></analytic><series><title level="j">Current topics in microbiology and immunology</title><idno type="ISSN">0070-217X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cytokines (immunology)</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (virology)</term><term>Lysophospholipids (agonists)</term><term>Lysophospholipids (therapeutic use)</term><term>Orthomyxoviridae (drug effects)</term><term>Orthomyxoviridae (immunology)</term><term>Sphingosine (agonists)</term><term>Sphingosine (analogs & derivatives)</term><term>Sphingosine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cytokines (immunologie)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Lysophospholipides (agonistes)</term><term>Lysophospholipides (usage thérapeutique)</term><term>Orthomyxoviridae ()</term><term>Orthomyxoviridae (immunologie)</term><term>Sphingosine (agonistes)</term><term>Sphingosine (analogues et dérivés)</term><term>Sphingosine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Lysophospholipids</term><term>Sphingosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sphingosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Lysophospholipides</term><term>Sphingosine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sphingosine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cytokines</term><term>Grippe humaine</term><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Lysophospholipids</term><term>Sphingosine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Lysophospholipides</term><term>Sphingosine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Orthomyxoviridae</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cytokine storm defines a dysregulation of and an excessively exaggerated immune response most often accompanying selected viral infections and several autoimmune diseases. Newly emerging and re-emerging infections of the respiratory tract, especially influenza, SARS, and hantavirus post considerable medical problems. Their morbidities and mortalities are often a direct result of cytokine storm. This chapter visits primarily influenza virus infection and resultant cytokine storm. It provides the compelling evidence that illuminates cytokine storm in influenza pathogenesis and the clear findings that cytokine storm is chemically tractable by therapy directed toward sphingosine-1-phosphate receptor (S1PR) modulation, specifically S1P1R agonist therapy. The mechanism(s) of how S1P1R signaling works and the pathways involved are subjects of this review. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24728596</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0070-217X</ISSN><JournalIssue CitedMedium="Print"><Volume>378</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Current topics in microbiology and immunology</Title><ISOAbbreviation>Curr. Top. Microbiol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.</ArticleTitle><Pagination><MedlinePgn>129-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-319-05879-5_6</ELocationID><Abstract><AbstractText>Cytokine storm defines a dysregulation of and an excessively exaggerated immune response most often accompanying selected viral infections and several autoimmune diseases. Newly emerging and re-emerging infections of the respiratory tract, especially influenza, SARS, and hantavirus post considerable medical problems. Their morbidities and mortalities are often a direct result of cytokine storm. This chapter visits primarily influenza virus infection and resultant cytokine storm. It provides the compelling evidence that illuminates cytokine storm in influenza pathogenesis and the clear findings that cytokine storm is chemically tractable by therapy directed toward sphingosine-1-phosphate receptor (S1PR) modulation, specifically S1P1R agonist therapy. The mechanism(s) of how S1P1R signaling works and the pathways involved are subjects of this review. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oldstone</LastName><ForeName>Michael B A</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA, mbaobo@scripps.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 MH084512</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH084512</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI009484</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI074564</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AI057160</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI009484</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI074564</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Curr Top Microbiol Immunol</MedlineTA><NlmUniqueID>0110513</NlmUniqueID><ISSNLinking>0070-217X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008246">Lysophospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>26993-30-6</RegistryNumber><NameOfSubstance UI="C060506">sphingosine 1-phosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>NGZ37HRE42</RegistryNumber><NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008246" MajorTopicYN="N">Lysophospholipids</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013110" MajorTopicYN="N">Sphingosine</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24728596</ArticleId><ArticleId IdType="doi">10.1007/978-3-319-05879-5_6</ArticleId><ArticleId IdType="pmc">PMC7121493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2011 Nov;85(21):11208-19</Citation><ArticleIdList><ArticleId IdType="pubmed">21865394</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(1):e29347</Citation><ArticleIdList><ArticleId IdType="pubmed">22235288</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respir Physiol Neurobiol. 2011 Jan 31;175(1):185-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21075220</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Chem Biol. 2011 May;7(5):254-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21445057</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1560-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19164548</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2010 Oct 01;5(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">20957032</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunity. 2007 Aug;27(2):240-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17723216</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2012 Sep;12(9):687-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22738893</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 2009;78:743-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19231986</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2009 Oct;5(10):e1000604</Citation><ArticleIdList><ArticleId IdType="pubmed">19798428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bull Hist Med. 2002 Spring;76(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11875246</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19218453</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 2013;82:637-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23527695</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2007 Nov;8(11):1188-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17952044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2012;17(1 Pt B):159-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22311680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2011;6(10):e26050</Citation><ArticleIdList><ArticleId IdType="pubmed">22022504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12018-23</Citation><ArticleIdList><ArticleId IdType="pubmed">21715659</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Pharmacol. 2008 Sep;74(3):896-903</Citation><ArticleIdList><ArticleId IdType="pubmed">18577684</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 2011 Sep 16;146(6):980-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21925319</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2006 Oct;12(10):1203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16964257</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2011 Jan 06;6(1):e16028</Citation><ArticleIdList><ArticleId IdType="pubmed">21253602</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Immunol. 2007 Mar;28(3):102-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17276731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19973-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21045126</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2007 Jan 18;445(7125):319-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17230189</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Disord Drug Targets. 2007 Dec;7(4):336-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18220965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Rosen, Hugh" sort="Rosen, Hugh" uniqKey="Rosen H" first="Hugh" last="Rosen">Hugh Rosen</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Oldstone, Michael B A" sort="Oldstone, Michael B A" uniqKey="Oldstone M" first="Michael B A" last="Oldstone">Michael B A. Oldstone</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002871 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002871 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:24728596
|texte= Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24728596" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |